HAT-field: a very cheap, robust and quantitative point-of-care serological test for Covid-19.

Etienne Joly[1] [*] and Agnès Maurel Ribes[2]

1 : Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, 31000, France

2 : Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, 31000, Toulouse, France

*: correspondence to EJ: atnjoly@mac.com

Abstract

We have recently described a very simple and cheap serological test called HAT to detect antibodies directed against the RBD of the SARS-Cov-2 virus. HAT is based on hemagglutination, triggered by a single reagent (IH4-RBD) comprised of the viral RBD domain fused to a nanobody specific for glycophorin, which is expressed at very high levels at the surface of human red blood cells (RBCs).

One of the main initial goals of this study was to devise a test protocol that would be sensitive and reliable, yet require no specialized laboratory equipment such as adjustable pipets, so that it could be performed in the most remote corners of the world by people with minimal levels of training. Because antibody levels against the viral RBD have been found to correlate closely with sero-neutralisation titers, and thus with protection against reinfection, it has become obvious during the course of this study that making this test reliably quantitative would be a further significant advantage.

We have found that, in PBN, a buffer which contains BSA and sodium azide, IH4-RBD is stable for over 6 months at room temperature, and that PBN also improves HAT performance compared to using straight PBS. We also show that performing HAT at either 4°C, room temperature or 37°C has minimal influence on the results, and that quantitative evaluation of the levels of antibodies directed against the SARS-CoV-2 RBD can be achieved in a single step using titration of the IH4-RBD reagent.

The HAT-field protocol described here requires only very simple disposable equipment and a few microliters of whole blood, such as can be obtained by finger prick. Because it is based on a single soluble reagent, the test can be adapted very simply and rapidly to detect antibodies against variants of the SARS-CoV-2, or conceivably against different pathogens. HAT-field appears well suited to provide quantitative assessments of the serological protection of populations as well as individuals, and given its very low cost, the stability of the IH4-RBD reagent in the adapted buffer, and the simplicity of the procedure, could be deployed pretty much anywhere, including in the poorest countries and the most remote corners of the globe.

Introduction

For the past two years, the Covid-19 pandemic has preoccupied the whole world, and it remains a major concern for all nations, albeit with different perspectives depending on their wealth. In affluent nations, most people have now been vaccinated, and the main issues now are when to start offering booster vaccinations and to whom. Poorer countries, by contrast, have had limited access to vaccines or even to diagnostic tests simply to follow the progress of the pandemic within their populations. For both affluent and less affluent countries, access to a robust and reliably quantitative point-of-care (PoC) serological test would be a great asset to tackle these problems. Such a test would allow health professionals, and health authorities, to distinguish people with either no or waning levels of antibodies, who should have priority for vaccination or re-vaccination, from those with high levels of antibodies against the SARS-CoV-2 virus, who may not need to be vaccinated or revaccinated immediately, and may actually be the ones most likely to suffer undesirable effects from vaccine injections.

Last year, we described a very simple, inexpensive serological test for Covid-19 called the HAT (hemagglutination test; (Townsend et al. 2021). HAT uses a recombinant protein (IH4-RBD) comprised of a nanobody, IH4, which binds to human glycophorin at the surface of red blood cells (Habib et al. 2013), fused to the receptor-binding domain (RBD) of the SARS-CoV-2 virus. When mixed with diluted human blood, this reagent coats the red blood cells (RBCs) and, if antibodies to the viral RBD domain are present in the blood sample, they will cause hemagglutination. This test thus detects specifically antibodies against the RBD, which means that it can be used as a surrogate sero-neutralization test since those antibodies are the main ones endowed with sero-neutralizing activity against the virus (Ertesvåg et al. 2021; Jeewandara, Kamaladasa, et al. 2021; Lamikanra et al. 2021). Another important feature of HAT is that, because it is based on a soluble reagent, it can be adapted very easily and rapidly to detect antibodies against different variant forms of the virus (Ertesvåg et al. 2021; Jeewandara, Kamaladasa, et al. 2021) or presumably to other pathogens if needed be, for example in the context of a newly arising pathogen.

In the format initially described for HAT, quantitative evaluation of the levels of antibodies was possible via serial dilutions of serum or plasma before mixing with washed autologous RBCs, or obtained from O- donors (Townsend et al. 2021). In this simple single-point format, HAT was recently used to measure seropositivity rates in Sri Lanka and compared well to a sensitive ELISA (Jeewandara, Guruge, et al. 2021). Here, we describe an adapted protocol, called HAT-field, which is quantitative through titration of the IH4-RBD reagent and can be performed in a single simple step with no specialized equipment. The observation that the performances of the assay are minimally affected by temperatures and that, in the optimized HAT-field buffer, which contains BSA and azide, the reagent is stable for weeks with no refrigeration required could also greatly facilitate the use of HAT-field in remote locations.

Results

BSA prevents adsorption of IH4-RBD to the reaction wells

Following the method originally described by Wegmann and Smithies (Wegmann and Smithies 1966), the original HAT protocol uses 96 conical-well plates (Townsend et al. 2021). When appropriately diluted blood is mixed with the IH4-RBD reagent in these conical wells, the RBCs sediment during the incubation of 60 minutes; hemagglutination due to specific antibodies against RBD in the blood is observed by the formation of persistent 'buttons' of RBCs in the bottom of the well when the plate is tilted, whereas in the absence of hemagglutination a 'teardrop' shape forms (Townsend et al. 2021).

To perform HAT in field conditions and/or on large numbers of samples, it would be much simpler for the users to be provided with the IH4-RBD reagent already distributed in the V-well plates used to perform the HAT tests. The plates, however, are made of polystyrene, to which many proteins tend to adsorb. (This non-specific adsorption is the basis for many ELISA tests; (Kenny and Dunsmoor 1983). Indeed, when the IH4-RBD reagent was diluted in PBS and placed in the wells, some of it was readily adsorbing to the plastic of the wells' slopes, and causing the formation of diffuse veils in hemagglutinated wells, which not only raised concerns about losing some of the active reagent by its immobilization on the plastic, but could make the reading of the results of the HAT tests less clear than the formation of bright red buttons (Figure 1A). Furthermore, in preliminary experiments involving serial dilutions of the IH4-RBD reagent, we found that the diluted IH4-RBD reagent tended to be lost rapidly through this phenomenon of adsorption.

We solved this problem of veil formation by diluting the IH4-RBD reagent in PBN (Figure 1A, right columns of each panel), which is PBS containing 1% BSA and 3mM sodium azide, to prevent contamination by micro-organisms. In PBN, rather than veils, buttons of hemagglutination were observed and could be distinguished easily from the teardrops in the negative controls. These buttons formed whether the RBCs, which were added after the IH4-RBD reagent, were resuspended in PBS, in PBS supplemented with 1% plasma from the same seronegative donor as the RBCs, or in PBN. We conclude from this experiment that veil formation is due to adsorption of the IH4-RBD reagent to the polystyrene walls of the wells. This interpretation is supported by our finding that no veils formed when the wells were precoated with BSA and rinsed with PBS before performing the assay (Figure 1B).

Figure 1: **BSA prevents adsorption of IH4-RBD to the reaction wells.**

A) HAT was performed in uncoated wells prefilled with IH4-RBD reagent diluted in either PBS (left columns) or PBS + 1% BSA + 3mM sodium azide (PBN, right columns). RBCs, resuspended in either PBS (left panels), in PBS supplemented with 1% seronegative autologous plasma (middle panels), or PBN (right panels) and various antibodies against SARS-CoV-2 were added to each well to test for hemagglutination. In the absence of antibody (Neg) the typical teardrop structure can be seen in each well. In the presence of a monoclonal antibody against RBD (CR3022), or plasma from convalescent Covid-19 patients, a veil structure forms in the absence of BSA, whereas a button forms when BSA is present. (see Methods for details)

B) HAT as in (A) but performed in wells precoated with BSA. In the presence of the monoclonal antibody or convalescent patient plasma, hemagglutination is observed as a button rather than the veils seen in (A). Similar data were obtained from three experiments.

Azide and BSA increase the sensitivity of HAT

To investigate whether the presence of BSA and azide diminishes the performance of the HAT, we diluted the IH4-RBD reagent in PBS, in PBS containing 3mM sodium azide (PBS-N3), or in PBN and used these diluted reagents to test hemagglutination of whole blood and O-RBCs from a sero-negative donor resuspended in 1% plasma from the same donor, in the presence of serial dilutions of either the monoclonal anti-RBD CR3022 or of an immune serum (Figure 2).

Figure 2: **Azide and BSA increase the sensitivity of HAT**

A) The effects of azide and BSA on HAT performed using RBCs from a seronegative donor resuspended in PBS, PBS-N3 or PBN and 1% plasma from the same donor, or with whole blood from the same donor, and with serial dilutions of an immune serum from a convalescent Covid-19 patient (Serum 197; left columns) or a monoclonal anti-RBD (CR3022; right columns). The three negative controls were: no antibody (0), neither antibody nor IH4-RBD, and the most concentrated serum or antibody condition with no IH4-RBD. Blue circles indicate the titration endpoints. (see Methods for details)

B) After HAT, the RBCs were resuspended, stained with a fluorescent secondary anti-human Ig antibody and analyzed by FACS. The numbers shown correspond to specific signals, i.e. the difference in GMFI values of each sample with that of the control sample incubated in the same buffer with no antibody or IH4-RBD. The squares highlighted in yellow indicate the titration endpoints.

Similar data were obtained from four experiments.

Rather than diminishing the performance of HAT, we found that the presence of azide improved its sensitivity: when HAT was performed in PBS-N3 rather than PBS, the titration endpoints (figure 2A, blue circles) were shifted by one double dilution (DD), and this occurred both with immune sera and with monoclonal antibodies. Addition of 1% BSA sometimes improved sensitivity by another DD, but we only saw this in some experiments, and not others.

To investigate the possible cause of the increased sensitivity of HAT in the presence of sodium azide, we used fluorescence-activated cell sorting (FACS) to analyze the amount of antibody bound to the RBCs at the end of the HAT. Dilution of the IH4-RBD reagent in PBS-N3 or in PBN resulted in a small increase in the amount of antibody bound to the surface of the RBCs, but not to an extent that would explain the increased sensitivity (Figure 2B). We postulate that the increased sensitivity due to the presence of azide may, instead, be primarily due to an 'ageing' effect on the RBCs (see Discussion)

IH4-RBD is very stable when diluted in PBN

For use in the field, it would be most convenient for the IH4-RBD reagent to be pre-distributed in the wells, raising the question of the stability of working dilutions of the reagent, both in the cold and at ambient temperatures. To investigate the stability of IH4-RBD, we prepared aliquots of IH4-RBD at 2 μg/ml in either PBS-N3 or in PBN, on various dates over the course of 15 months and stored those aliquots at 4°C, room temperature (RT) or 37°C. Those IH4-RBD aliquots of various ages were then used to perform HAT titrations of the reagent in the presence of constant amounts of the CR3022 monoclonal antibody (Figure 3). In some experiments, to evaluate more precisely the remaining activity of IH4-RBD after incubation, we also quantified the amounts of antibodies bound to the surface of the RBCs by using FACS (red numbers in Figure 3).

Figure 3: IH4-RBD is very stable when diluted in PBN

The effects of long-term storage of IH4-RBD in PBS-N3 or PBN at 4°C, RT and 37°C, as determined by HAT and by FACS analysis of antibody binding to RBCs after HAT. Hemagglutination end-points in the presence of the CR3022 monoclonal antibody at 100 ng/ml (black circles) were determined by titration of aliquots of working dilutions of IH4-RBD stored for up to 15 months at the indicated temperatures. The red numbers indicate the intensity of the specific fluorescent staining recorded by FACS analysis performed after the HAT assay on the RBCs from the samples incubated with 100 ng/ml IH4-RBD (see Methods for details). Similar data were obtained in seven experiments, some of which also included using diluted sera from convalescent patients in parallel to the CR3022 monoclonal antibody (not shown).

By performing such experiments repeatedly, we found that IH4-RBD is remarkably stable when diluted in PBN: no significant loss of activity was seen for any of the IH4-RBD PBN dilutions kept for over a year at 4°C, and this was true for up to 6 months at room temperature. At 37°C, we did see some progressive loss of activity, but this only resulted in the loss of one DD in HAT sensitivity at 9.5 months (after 15 months, evaporation had caused the loss of what was left of the aliquots kept at 37°C).

On the other hand, the activity of IH4-RBD dilutions prepared in PBS-azide were usually already lower by one DD than those prepared in PBN on day zero. Furthermore, we observed marked variability over time between the IH4-RBD dilutions prepared in PBS-azide on different dates: some batches showed a drop of just one DD compared to the dilutions prepared in PBN, and stayed stable for many weeks after this; for others, however, we witnessed much more marked losses over time, dropping to undetectable levels after just a

212 few weeks, even for tubes kept at 4°C. In retrospect, we suspect that this variability may be
213 linked to the fact that, because the Covid-19 crisis had caused a penury of plasticware,
214 different types and brands of plastic tubes had to be used to prepare and stock the IH4-RBD
215 dilutions on different dates, and those different tubes probably had different protein-
216 binding capacities, resulting in the variable loss of the diluted IH4-RBD protein.
217
The important take-home message we draw from this set of experiments is that, regardless
of the brand or type of plastic tubes used, as long as IH4-RBD was diluted in PBN, the activity
of the diluted stocks was always remarkably reproducible, and stable for over a year if kept
at 4°C, and with only marginal losses for dilutions kept at room temperature or 37°C. This
remarkable stability of IH4-RBD, which is the sole reagent required for HAT, could greatly
facilitate making this serological test available to populations living in remote environments,
with no access to refrigeration.
225
Temperature has little influence on HAT results
For use as a PoC test in the field, the HAT should be robust in many environments and, in
particular, at a broad range of temperatures. To evaluate how temperature influences the
results of the HAT, we set-up three identical 96-wells plates for 2D titration experiments (i.e.
double dilutions of antibodies in one direction, and of the IH4-RBD reagent in the other) and
incubated those at three different temperatures: at 4°C (on ice in a cold room), at RT (*ca.*
21°C), and at 37°C (in a CO_2 cell culture incubator; Figure 4).
233

234
Figure 4: **Temperature has little influence on HAT results**
To determine the effect of temperature on the performance of HAT, three parallel plates were setup
for 2D titrations, with DD of IH4-RBD going from 8 µg/ml to 8 ng/ml along lines, and DD of two
different immune sera from convalescent Covid-19 patients down columns (see Methods for
practical details). After incubation at the indicated three temperatures, no substantial differences
were seen in titration end-points (blue circles). Similar results were obtained in 3 independent
experiments, using a total of 3 different immune sera, 2 plasmas, and the CR3022 monoclonal
antibody.
243
244

245 Incubation temperature had little or no discernable influence on the hemagglutination
246 endpoints (blue circles), with the possible exception of the wells containing the highest
247 concentration of IH4-RBD and very diluted sera, where incubation at 4°C resulted in a small
248 improvement in sensitivity when compared to the assays performed at RT or 37°C.
249
250
The HAT-field protocol
The observation that, in 2D titrations such as those shown in Figure 4, the titration
endpoints were distributed in an almost linear fashion on an X–Y axis suggested to us that a
quantitative version of HAT might be developed by using dilutions of IH4-RBD rather than by
using serial dilutions of plasma or sera and donor RBCs. We have now devised such a
quantitative protocol, which only requires, for each test, one lancet, one plastic Pasteur
pipet, one plastic tube containing 300 μl of PBS–2mM EDTA, 10 μl of whole blood, and one
column of 8 conical wells on a 96-well plate, preloaded with 60 μl/well of a range of
concentrations of IH4-RBD (Figure 5).
260
The lancet is used to express a lentil-size drop of capillary blood from a clean fingertip of the
subject to be tested. The plastic Pasteur pipet is used to collect 10 μl of that blood, which
corresponds to filling the first section of the pipet (the precise volume of blood collected is
not critical; it may vary by as much as 30% with no detectable influence on the results). The
blood is diluted *ca.* thirty-fold in the tube containing 300 μl of PBS - 2mM EDTA. The same
pipet is then used to collect all 310 μl of this diluted blood and to transfer one drop into
each of the 8 wells of a 96-well plate, prefilled with 60 μl of PBN containing 7 concentrations
of IH4-RBD, and a negative control well containing either PBN or IH4 alone (not fused to
RBD) diluted in PBN to a similar molar concentration as the highest IH4-RBD concentration
used. As for the original HAT, the plate is incubated at room temperature, tilted after 60
minutes, and photographed after *ca.* 20 seconds. The photograph will later be used to score
the samples. Scoring simply corresponds to the number of fully hemagglutinated wells in a
column, and thus goes from 0 (no hemagglutination in the well with the highest
concentration of IH4-RBD, i.e. 3.16 μg/ml) to 7 (full hemagglutination in the well with the
lowest concentration of IH4-RBD, i.e. 3.16 ng/ml). For the tilting and the photographing, we
find it convenient to use a very simple home-made light box (see tutorial) and a standard
smart phone camera.
278

Figure 5: Schematic description of the HAT-field protocol

One limitation of HAT is that it is not as sensitive as ELISA, CLIA (chemiluminescence immunoassay) or FACS (Maurel Ribes et al. 2021; Lamikanra et al. 2021). As we have seen above (Figure 4), increased sensitivity can be attained by the use of more IH4-RBD reagent, but we found that another way to increase HAT sensitivity was to perform prolonged incubations. After 5 hours, for example, we saw a very significant improvement in sensitivity, with the titration endpoints increasing for most samples by 2 or 3 dilution points when compared to those after 60 minutes, with fewer and fewer samples that were detected positively by FACS remaining below the threshold value of 1 for HAT-field (Figure S1, first line).

Such long incubations are, however, not practical for a test intended for use in field settings. To overcome this problem, we found that centrifugation of the plates at 100g for 1 minute increased sensitivity to a level equivalent, or even slightly superior to that of incubating the plates for 5 hours. This centrifugation step, moreover, may be performed 15 minutes after distributing the diluted blood in the plate, with similar results to those obtained if the plates were centrifuged after 60 minutes incubation (Figure S1, second line). With access to the means to centrifuge the assay wells (which can be achieved in adapted salad-spinners, see Discussion), the HAT-field protocol can thus be completed in less than 30 minutes, which would be compatible with performing it in certain field settings, for example in the context of vaccination centers, to identify individuals with high levels of antibodies, who might not need to be vaccinated or re-vaccinated.

Validation of the HAT-field protocol

To validate the performance of the HAT-field protocol, we used a panel of 60 EDTA whole-blood samples collected in early September from patients in the hematology department of Toulouse University hospital. The samples were picked randomly from clinical samples left over after the prescribed hematology analyses had been performed. At that time, over 85% of the adult population had been vaccinated in France, and we thus expected a large proportion of the samples to be seropositive against the S protein of SARS-CoV-2, albeit at various levels.

The results obtained by HAT-field on these 60 whole blood samples were compared with those obtained by testing the plasma from the same samples by using the original HAT protocol with donor RBCs (Townsend et al. 2021), and by using the FACS-based Jurkat-S&R-flow test (Maurel Ribes et al. 2021), which is very sensitive, quantitative, and allows isotyping of the antibodies reacting against the S protein (Figure 6).

Figure 6: **Validation of the HAT-field protocol by comparison with laboratory tests**
Sixty randomly selected blood samples were used to compare the results of the HAT-field protocol with those of HAT plasma titrations and the Jurkat-S&R-flow test (see Methods). The graphs show one-on-one comparisons of the results obtained with those three tests, as indicated, using the values obtained by centrifuging the plates after 15 minutes (for HAT-field), and after 60 minutes for plasma titrations. Pearson's correlation coefficients are indicated in the bottom right corners. The dotted line in the left graph indicates the position of the median, and those in the middle and right graphs indicate the threshold for positive samples in the Jurkat-S&R-flow. The two red dots in each graph correspond to two negative samples, which gave false-positive results in HAT due to their reactivity against the IH4 nanobody moiety of the reagent. The orange dots correspond to samples positive in the Jurkat-S&R-flow test that showed some reactivity against the IH4 nanobody alone, albeit with lower titers than against the IH4-RBD reagent. For the sample represented by an orange dot surrounded by a red circle on the right graph, the plasma titration against the nanobody alone was positive, but it led to only partial hemagglutination with the IH4-RBD reagent (for actual values, see sample 48 in data file).

The very good correlation between the results of all three tests validates that the HAT-field protocol can be used for quantitative assessment of the levels of antibodies contained in a whole-blood sample in a single step, without the sophisticated equipment needed for the Jurkat-S&R-flow test, and without needing to separate the RBCs from plasma or serum and having access to RBCs from an O- donor, as in the experiment using the original HAT to perform plasma titrations.

HAT-field works with Delta-variant IH4-RBD

Our IH4-RBD reagent was designed to present the RBD sequence of the original Wuhan variant (residues 340–538 of the S protein; (Townsend et al. 2021). At the time of our study, however, a large proportion of the SARS-CoV-2 viruses circulating in France belonged to the Delta variant lineage (see epidemiological report here), which has two mutations in the RBD domain (L452R and T478K in the B.1.617.2 strain) (Ertesvåg et al. 2021; Jayathilaka et al. 2021). We therefore wanted to compare the results obtained with the IH4-RBD-Wuhan reagent (used above) with a reagent that incorporates the two mutations in the Delta variant, IH4-RBD-Delta. We tested the 60 blood samples with the IH4-RBD-Wuhan and IH4-RBD-Delta reagents in both the HAT-field and original HAT plasma titration assays. For most samples, the scores obtained were one or two units higher when the Wuhan IH4-RBD reagent was used than those with the IH4-RBD-Delta reagent (Figure S3). This is consistent with a previous report that, in vaccinated people, HAT titers obtained with the IH4-RBD-Delta tend to be lower than with the IH4-RBD-Wuhan (Jayathilaka et al. 2021), and with the fact that, at the time of our study, most people in the French population had antibodies due to being vaccinated and not as a consequence of a previous infection by the SARS-CoV2 virus (retrospective analysis of clinical information on our cohort of 60 blood samples revealed that only three samples were from patients who had ever had a positive PCR test for SARS-CoV-2 (see data file and Figure S3).

Discussion

The aim of this project was to define a HAT protocol that could be used in the field. As such, the HAT-field protocol needed to work with satisfactory sensitivity on capillary blood, and to involve no specialized laboratory equipment such as adjustable pipets and disposable tips. In the course of our efforts, we discovered that i) the use of PBN results in markedly improved HAT robustness and sensitivity ii) HAT sensitivity is markedly improved by prolonged incubations (or by brief low-speed centrifugation), albeit with a parallel drop in specificity iii) quantification could be achieved by titrating the IH4-RBD reagent rather than the plasmas or sera. Incidentally, we realized recently that such an approach of titrating the RBC-binding reagent had been suggested previously for an HIV serodiagnostic test (Kemp et al. 1988).

PBN is a buffer containing both 1% BSA and azide, which has several concomitant advantages: i) Used as a dilution buffer for the IH4-RBD, it blocks the reagent's nonspecific adsorption to plastic, and results in its much improved stability over time, even if kept out of the cold. ii) The conjoint action of azide and BSA results in increased sensitivity, probably because they both improve the settling of the RBCs at the bottom of the wells. iii) In experiments which involve the use of O- RBCs, for example when using HAT to titrate plasmas or sera, the use of whole blood (or the addition of 1% seronegative plasma or serum) is no longer necessary when PBN is used to prepare a suspension of washed O- RBCs. We feel that this advantage is quite significant since most blood donors in the population have now become seropositive because of vaccinations.

As we have seen, the improvement of HAT sensitivity provided by prolonging incubations up to 5 hours can be very advantageously replaced by a brief step of centrifugation at 100g, which can be performed after only 15 minutes of incubation. The need for a centrifuge with the capacity to spin 96 well plates would, however, rather preclude the possibility of performing HAT in the field. But accelerations of 100g are in the range of those attained by

hand-driven centrifuges such as [salad spinners](). We have investigated the possibility of using
this type of centrifuge for spinning 96 well plates after just 15 to 20 minutes of incubation,
but have found that this only works for the central 2 columns of a 96 well plate because the
RBCs in the outer columns are pushed to the outside of the wells. Whilst it is hard to
conceive that hand-driven centrifuges with the capacity to spin 96 well plates in swinging-
out trays could become part of the equipment enabling the use of HAT in the field, a rather
simple solution would be to design plastic strips of conical wells for individual tests. Using
very simple adapters, those purposefully designed sets of wells could then be spun in hand-
driven centrifuges of the salad spinner type. The design, and manufacture, of such
disposable strips of wells, which would necessarily require the involvement of an industrial
partner, was, however, well beyond the means of this study.
405
One important consideration about performing centrifugation at the end of a HAT assay is
that, whilst this works very well with RBCs contained in whole blood samples, or with
washed RBCs from freshly collected blood, we found that it can become problematic with
RBCs that have been stored at 4°C for more than a week. Over time, stored RBCs will indeed
progressively lose their capacity to teardrop, which can, incidentally, result in a slight
improvement of the apparent sensitivity of HAT assays performed under simple gravity.
But, if submitted to accelerations of 100g, we have found that such "aged" RBCs will form
compact pellets that will fail to teardrop, even upon prolonged tilting of the plate. (of note,
this is also the case for RBCs that have been kept in azide for a few hours. Preparing
suspensions of RBCs in PBN should thus be done just before performing the HAT assays).
416
When performing HAT in PBN compared to PBS, we observed an increase in sensitivity which
we suspect is most probably due to an improved sedimentation of the RBCs, with both azide,
and BSA, contributing to the formation of more compact pellets at the bottom of the V-
shaped wells. Regarding the role of azide, we postulate that, by blocking the metabolism of
the RBCs, it probably increases their density and consequently their sedimentation.
Regarding the beneficial role of facilitating the sedimentation of RBCs, this is something that
Weggmann and Smithies had recognized soon after their initial description of the microtiter
hemagglutination method, and for which they had proposed using paraffin-coated plates as
an improvement (Wegmann and Smithies 1968). We feel, however, that the use of PBN as
the diluting buffer of the IH4-RBD reagent is much simpler than that of paraffin-coated
plates, and, as will be seen below, this has several other advantages, including the
improvement of the stability of the reagent over time.
429
Whilst HAT was, from its initial conception, always intended primarily to be carried out on
capillary blood obtained by fingertip pricks, because of regulatory restrictions, all the
experiments described in this paper had to be performed on samples of venous blood
collected by phlebotomy. A recent study has shown that, as could be expected, HAT
performed on capillary blood gives the same results as on venous blood samples (Ertesvåg et
al. 2021), and preliminary results which we have obtained recently suggest that the results
of the HAT-field protocol performed on capillary blood indeed correlate just as well with
those of the Jurkat-S&R-flow test as those obtained with venous blood (Joly et al., man. in
prep.)
439
440

In their original paper, Wegmann and Smithies had described using incubations of 4 to 6 hours as their standard protocol, and suggested that a brief step of centrifugation could be used as an alternative (Wegmann and Smithies 1966). For the record, during the initial stages of this study, we had made several attempts to use centrifugation, but we did not have access to whole blood samples at the time. We were thus using O- RBCs which had often been stored at 4°C for up to several weeks, and had initially given up on centrifugation because the aged RBCs we were using failed to teardrop after centrifugation. Incidentally, in that same paper, Wegmann and Smithies also suggested using BSA as an alternative to serum or plasma to promote better RBC settling patterns. They were, however, recommending using BSA at 0.22% which we found to be less effective than 1% to block the adsorption of the IH4-RBD reagent to plastic.

Once we had found that the use of centrifugation, combined to that of PBN as a buffer, could result in a marked improvement of the sensitivity of the 'standard' HAT assay in test samples, we needed to validate the performance of the modified HAT assay on clinical samples. For this, we made use of a cohort of 60 clinical blood samples of unknown serological status, and characterized those using the Jurkat-S&R-flow test, which is both extremely sensitive, quantitative, and allows the semi-quantitative isotyping of the plasmatic antibodies (Maurel Ribes et al. 2021). As seen on figure 6, we found very good correlations between all three tests: HAT-field, HAT plasma titrations, and the Jurkat-S&R-flow test.

On the graph on the left of figure 6, which compares the scores of titrations by standard HAT to those obtained with HAT-field, most points are sitting above the median line, with several points (corresponding to 10 samples, see data file) not scoring positive by HAT-field (i.e. a score < 1) whilst being positive by standard HAT titration (i.e. score ≥ 1). In the conditions used in this study, the HAT-field protocol was thus markedly less sensitive than the optimized standard HAT approach, which can be explained by the conjunction of 4 factors:
a) For titrations by standard HAT, we used plasmas at 1/50 as the highest concentration. In other words, we used 2 µl of plasma per well, to react against 0.3 µl of RBCs. The plasma to RBC ratio was thus six times more than in HAT-field, where there are roughly equivalent volumes of RBCs and plasma, and this ratio of 1 cannot be altered since, in HAT-field, the blood samples are simply diluted before performing the assay. On this subject, we have found that increasing the amount of whole blood per well (in other words using blood that is less dilute) has very little influence over the HAT-field results, and, if anything, adding more blood can sometimes reduce the sensitivity, albeit never by more than 1 dilution.
b) Titrations for figure 6 were carried out on washed RBCs from an O- donor that were 5 days old, and, in our hands, RBCs which have been washed and stored at 4°C for a few days tend to work a bit better for HAT than those in whole blood.
c) When using washed RBCs, EDTA is no longer present, and we have found that excess EDTA can reduce HAT sensitivity for certain samples, possibly because the binding of certain antibodies may involve divalent cations. In the future, it may thus be interesting to explore the possibility of using heparin rather than EDTA as an anticoagulant.
d) Whilst plasma titrations were carried out by double dilutions of the plasmas, in the optimized protocol we have devised for HAT-field, the IH4-RBD reagent is titrated in steps of 3.16 fold, so as to cover a broader range (see Methods). This does, however, only really influence the upper right corner of the graph, i.e. the scores of samples with very high levels of antibodies.

On the right panel of figure 6, one finds four samples that scored positive by standard HAT, whilst the staining values in the Jurkat-S&R-flow test were in the doubtful zone between 10 and 40, and our view is that those samples probably contained some antibodies reacting specifically against the SARS-CoV-2 spike protein, and their more effective detection by hemagglutination than by FACS staining may be due to relatively high proportions of IgAs or IgMs. This is indeed reminiscent of the observation reported in our first paper that HAT could detect antibody responses during very early SARS-CoV-2 infections before CLIA (Townsend et al. 2021). Incidentally, although this is not something that we have yet managed to document formally, we noticed that the samples which contain sizeable amounts of IgMs and/or IgAs often reach higher HAT scores than expected from the FACS results obtained with the pan-human Ig secondary antibody, with even higher scores by plasma dilutions than in HAT-field (see data file). Of note, for sample 19, which was a false positive and gave very high titers against that IH4 alone, FACS analysis performed after the HAT assay showed that the human antibodies bound to the IH4-coated RBCs were predominantly IgMs (data not shown).

For one sample (n° 48 in data file), indicated by an orange symbol with a red circle in Figure 6, the result of Jurkat-S&R-flow test was 44.84, i.e. just above the threshold value which is arbitrarily set to 40. This sample only led to partial hemagglutination at 1/50 in the standard HAT, but showed reactivity against the IH4 nanobody alone with an endpoint at 1/200 after centrifugation (score 3). We thus surmise that this sample does contains either very low or no specific anti-SARS-CoV-2 antibodies, which provides a justification for maintaining the Jurkat-S&R-flow test threshold at its current value.

As in all biological tests, increasing the sensitivity will almost unavoidably lead to an increase in the proportion of false positives. It is thus not surprising that, with the gain of sensitivity of HAT afforded by the combined use of PBN and spinning, the proportion of samples being detected as showing some reactivity against the IH4 nanobody should be higher than the 1 to 2% that were originally detected with the standard HAT protocol in various cohorts (Townsend et al. 2021; Maurel Ribes et al. 2021).

In our current cohort, with the HAT-field protocol, reactivity against the IH4 moiety was detected in 3% of samples (2 out of 60) after one hour under normal gravity, and climbed to 8 % (5 out of 60) after spinning. With the more sensitive protocol used for plasma titrations, 5 samples (8%) reacted against the IH4 nanobody after one hour under simple gravity, but this number climbed to 12 (20% of samples) after spinning. If the HAT-field test was ever to be used in a clinical context, the results would be invalidated for those samples found to react with the IH4 alone, and with such high frequencies as we have observed in our small cohort, this could be a significant problem. An alternative would be to perform, from the start, systematic parallel titrations of the IH4-BRD and IH4 alone reagent, in order to identify samples which react markedly better on IH4-RBD than on IH4 alone. This could be achieved either by using 20 µl of blood diluted into 600 µl to distribute in two sets of 8 wells, which would be quite easy since 20 µl corresponds to the second section on the plastic Pasteur pipets. Alternatively, titrations of the two reagents could be carried out over just 4 wells each, with larger dilution factors (e.g. 10 fold) between wells.

In future, to reduce the proportion of false positives due to reactivities with the IH4 moiety, it may be interesting to investigate if the nanobody, which is of camel origin, could be somewhat "humanized" by site-directed mutagenesis without losing its capacity to bind to human glycophorin. Alternatively, the use of different antibodies binding to glycophorin, such as nanobodies derived from other species, or mAbs such as the one described by Kemp and colleagues (Kemp et al. 1988; Wilson et al. 1991) could also be explored as an alternative.

Two recent reports have described that HAT could be performed on cards rather than in V-shaped wells, with semi-quantitative results being obtained in minutes, which was made possible by the use of much higher amounts of the IH4-RBD reagent than when HAT is performed in V-shaped well (Kruse et al. 2021; Redecke et al. 2021). Reliably quantitative card-based tests HAT test would unquestionably be a very attractive solution for performing the test in field settings. Comparing the sensitivity, specificity and robustness of the two types of protocols, on cards or in V-shaped wells, on the very same cohorts of whole blood samples would be very interesting, especially if such comparisons were performed by third party laboratories.

Conclusion

We have shown that the HAT-field approach, which uses a single drop of capillary blood, can provide, in a single step, a quantitative measurement of the antibodies against the viral RBD, which are those endowed with neutralizing activity. Such a test could prove very useful for identifying individuals in need of a vaccine boost (or a primary injection). Given its very low cost, the stability of the IH4-RBD reagent, and the simplicity of the procedure, HAT-field should be well suited to be performed pretty much anywhere, including in the poorest countries and the most remote corners of the globe. Given that HAT has already been successfully adapted to detect antibodies against the RBD of several SARS-CoV2 variants (Ertesvåg et al. 2021; Jeewandara, Kamaladasa, et al. 2021), we presume that it could be adapted very rapidly to evaluate the levels of antibodies reacting against the RBD of other newly arising SARS-CoV2 variants of concern, such as the newly arisen and very divergent Omicron variant, or, in future, to pretty much any new threatening pathogen, and could thus represent a great asset to be better prepared to face future pandemics.

Methods
Reagents
PBS and tissue culture media were all obtained from Gibco.

BSA Fraction V was obtained from Sigma (ref A8022 or A7888). Of note, we have tried using other sources of Fraction V BSA for preparing PBN, and found that they do not all work as well as the ones listed above to prevent veil formation in HAT.

Sodium azide (NaN3, Sigma S2002) was prepared as a 20% stock solution in milli-Q water and kept at room temperature. This 3M solution was then used as a 1000x stock for the preparation of PBN, PFN and PBS-azide.

PBN was prepared by adding 500 µl of the above 1000x Azide stock and 5 grams of BSA Fraction V (Sigma A8022) to 500 ml of PBS.

PFN, used for the dilution of antibodies and washes of FACS samples, was prepared by
adding 500 µl of the above 1000x azide stock and 10 ml of fetal calf serum to 500 ml of PBS
(we find that this is a very good use for unwanted or expired stocks of FCS that often clutter
the bottom of freezers)

Because they contain azide (final concentration 3mM), no sterilizing filtration is needed for
either PBN or PFN, and they can be kept for many weeks at 4°C.

Polyclonal anti-human Igs secondary antibodies, all conjugated to Alexa-488, were from
Jackson laboratories, and purchased from Ozyme (France) . Refs: anti-human Ig-GAM: 109-
545-064, -G: 109-545-003, -A: 109-54-011, -M: 109-545-129

Anti RBD monoclonal antibodies: CR3022 (ter Meulen et al. 2006) and EY6A (Zhou et al.
2020) were obtained using antibody-expression plasmids, as previously described
(Townsend et al. 2021).

Covid-19 sera 186, 197 and 203 were obtained from the virology department of the
Toulouse hospital; plasmas 79 and 206 were from whole blood samples used in our previous
paper describing the Jurkat-S&R-flow test (Maurel Ribes et al. 2021)

IH4-RBD (Wuhan and Delta) and IH4 alone were produced by transient transfection of HEK-
293T cells, and purified from the supernatant by HIS-tag affinity purification, as previously
described (Townsend et al. 2021). Highly concentrated stock solutions at 3 – 5 mg/ml in PBS
were kept frozen as aliquots. Those were then used to prepare 100X stocks in either PBS or
PBN, which were kept frozen, and kept a 4°C after thawing for up to a few weeks.

To study the stability of the IH4-RBD reagent over time, working solutions at 2 µg/ml in
either PBS-azide or in PBN were prepared from 100X PBS stocks at various time points over
the course of a whole year. Three aliquots of 500 µl each were then set aside from those
working stocks, to be kept either at 4°C, at room temperature or at 37°C in a tissue culture
incubator. The activity of those aliquots of working stocks was then evaluated at regular
intervals by performing titrations of the IH4-RBD reagent against either the CR3022
monoclonal antibody diluted to a final concentration of 100 ng/ml, or various immune sera
diluted to give similar endpoint to those obtained with CR3022.

When comparing the reactivities against the Wuhan and Delta IH4-RBD reagents, we
ascertained that we were using working concentrations of the two reagents with
comparable activities by performing titrations with two monoclonals, EY6A or CR3022, which
recognize a binding site not affected by the two mutations carried by the RBD of the Delta
viral lineage, and found the Wuhan and Delta reagents to have indistinguishable
hemagglutinating activities under those conditions.

626
627

628 **Ethical statement**
629 RBCs from O- blood donors were obtained from the Toulouse branch of the Etablissement
630 Français du Sang (EFS), with whom the project was validated under agreement n°
631 21PLER2020-025**.**
632
Whole blood samples**:** The 60 samples used for figures 6 , S1, S2 and S3 were routine care
residues from patients of the Toulouse hospital, where all patients give, by default, their
consent for any biological material left over to be used for research purposes after all the
clinical tests requested by doctors have been duly completed.
According to the French law on ethics (loi Jardé), retrospective/prospective studies based on
the exploitation of clinical care residues do not require to be submitted to an ethics
committee. This study was reviewed and approved by the 'Directeur de la Recherche et de
l'Innovation du CHU de Toulouse', who confirmed that this study conformed with all the
ethical and legal requirements, and gave his signed approval with the agreement number
RnIPH 2021-99. This was further confirmed by the signature of Material Transfer Agreement
between the Toulouse University Hospital and the CNRS, with the following references:
Toulouse Hospital n° 20 427 C, CNRS n° 227232.
645
Human samples
The 60 whole blood samples were collected, regardless of gender, in the course of the
month September 2021. Those were anonymized within 24 hours of collection, transferred
from the hospital to the research lab, and kept at room temperature until being used for
HAT assays within 24 hours (i.e. less than 48 hours after blood samples were collected). In
trial experiments, we had found that such samples could be stored for up to 5 days without
any noticeable difference in the performance of the HAT tests.
653
654 After the whole blood samples had been used for HAT-field assays, the tubes were then
655 spun, the plasmas harvested into fresh tubes, and sodium azide added to 3 mM final. Those
656 harvested plasmas were kept at 4°C until they were used to perform the Jurkat-S&R-flow
657 tests and HAT assays for plasma titrations.
658
659 The identities, clinical conditions and Covid status (PCR or positive serology) were unknown
660 to the person performing the HAT experiments and Jurkat-S&R-flow tests.
661
Blood samples from O- donors (6 ml EDTA tubes) were obtained every few weeks from the
EFS (Toulouse blood bank). Whilst whole blood is best kept at room temperature (i.e.
between 20 and 25 °C), and can then only be used for HAT assays for up to 5 or 6 days,
washed red blood cells can be kept for several weeks, as long as they have been separated
from the white blood cells, and are kept at 4°C in the right buffer (in our case Alsever's
solution, Sigma A3551).
668
For preparing RBCs for storage at 4°C, we used the following standard protocol. The EDTA
collection tube is spun at 1000g for 20 minutes with no refrigeration, and the centrifμge
brake set to 2 /9. The plasma is collected into a separate sterile tube and a total of 8 ml of
sterile PBS used to resuspend the cells and transfer them to a 15 ml tube, on top of a 3 ml
cushion of lymphocyte separation medium (Corning Ref 25-072-CV). This tube is then spun
once more at 1000g for 20 minutes with no refrigeration, and the centrifμge brake set to 2
/9. The supernatant, including the ring of white blood cells, is aspirated and discarded. The

RBC pellet is then washed twice with 8 ml sterile PBS, once in 8 ml Alsever's solution, before
adding two volumes of Alsever's solution to the one volume of packed RBCs. This tube of
RBCs (at 30% v/v) can then be stored at 4°C, and used for HAT assays for several weeks.
After a week of storage, however, we found that the RBCs progressively tend to lose their
capacity to teardrop after spinning.
If whole blood from an O- donor was needed for experiments (e.g. as in Figure 2), 100-200 µl
were transferred to a separate sterile tube before performing the above procedure, and this
tube was kept at room temperature for a maximum of 4 days. Worthy of note, whilst all
donors were seronegative at the start of this study (i.e. from summer 2020 to winter 2021,
the proportion of seropositives started increasing in the spring 2021, correlating with the
proportion of vaccinated people increasing in the French population, and we have come
across no seronegative samples among the dozen of blood samples we have used since the
beginning of the summer 2021. Whilst the serological status of the donors does not matter
when working with washed RBCs, it would thus no longer be practical to plan performing
HAT tests in the presence of 1% autologous plasma as originally recommended (Townsend
et al. 2021), but, as shown in figure 1, this is no longer necessary in the presence of 1% BSA.
692
Original HAT assays
For HAT assays performed under 'standard' original HAT conditions, outside of using PBN
instead of PBS, we used similar reagent concentrations and incubation conditions to
those defined in our original description of HAT (Townsend et al. 2021):
- in a final volume of 100 µl per well
- with approximately 0.3 µl of packed RBCs per well, i.e. 1 µl of 30 % stock stored in
Alsever's solution.
- using IH4-RBD at a final concentration of 1 µg/ml (i.e. 100 ng/well), or alternatively 0.5
µg/ml of IH4 alone since the sequences of the nanobody and the His tag represent slightly
less than half of the IH4-RBD recombinant protein.
- Taking pictures after incubating the plates for 60 minutes at room temperature, for which
we find it very convenient to use a very simple home-made lightbox
(https://youtu.be/e5zBYd19nIA).
706
707 For experiments such as that presented in Figure 1, tubes of the appropriate 2X stocks
708 containing either the RBCs and the antibodies, or the IH4-RBD reagent were prepared to be
709 mixed 50/50 in each well.
710
For titration experiments, we prepared stocks containing RBCs and the appropriate amount
of the reagent to be kept constant (either the IH4-RBD reagent at 1 µg/ml or IH4 alone at 0.5
µg/ml for plasma titrations, or the appropriate antibody dilution for IH4-RBD titrations). 100
µl of those stocks were then distributed per well, and 200 µl for the wells of the first row.
The reagents to be titrated were then added to each of the wells of the first row, and a
multi-channel pipet was then used perform the serial dilutions by successive transfer of 100
µl to the wells of the adjacent row, with thorough mixing by pipetting gently up and down at
least 6 times at each diluting step.
719
720 A similar method was used to perform the 2D titrations presented in figure 4, filling columns
721 of wells with stocks of IH4-RBD serially diluted with the appropriate suspension of RBCs, and
722 proceeding in a second stage to perform serial dilutions of the antibodies in rows, as
723 described above.

HAT-field assays

The optimized procedure we have arrived to and used for this study is based on using 7 serial dilutions of the IH4-RBD reagent. Rather than double dilutions, we elected to use 3.16 as a dilution factor between adjacent wells. This not only allows to cover a larger range of IH4-RBD concentrations, but because 3.16 is the square root of 10, two successive dilutions conveniently correspond to a factor of 10. The concentrations of the IH4-RBD stocks used to prefill the wells were thus, in ng/ml 4750, 1500, 475, 150, 47, 15, 4.7. After addition of one drop of diluted blood, i.e. roughly 30 µl, the final volume was thus ca. 90 µl, and the approximate final concentrations of IH4-RBD in the wells were thus, in ng/ml: 3160, 1000, 316, 100, 31, 10, 3.1.

A detailed step by step protocol on how to generate the stocks of those various dilutions, and how to perform the HAT-field test, is provided as supplementary material.

For every sample, the eighth well of a row is allocated to performing the very important negative control, which can consist of either PBN, or preferably PBN containing the IH4 alone, i.e. the nanobody without the RBD attached to it, at 1.6 µg/ml final concentration, corresponding to a molar concentration similar to that found in the well with the highest concentration of IH4-RBD.

For the 60 samples of the cohort used in our study, because we were running sets of parallel HAT-field assays with either the IH4-RBD-Wuhan or IH4-RBD-Delta reagents, we performed both types of negative controls by using PBN as a negative control in the plates for the Wuhan HAT-field assays, and IH4 alone as a negative control in the plates for the Delta HAT-field assays. As discussed above, we found that the negative controls using the IH4 alone were much more informative.

For spinning the plates at 100g for 1 min, we used a centrifuge with swinging-out trays (Eppendorf 5810R, set to 705 rpm)

Jurkat-S&R-flow

Briefly, Jurkat-S and Jurkat-R cell lines, obtained and grown as previously described (Maurel Ribes et al. 2021), were resuspended in their own tissue culture medium at a concentration of 2.2×10^6 cells/ mL before pooling equal volumes of the two.

Plasmas to be tested were diluted 1/10 in PFN (PBS / 2% FCS / 200 mg/L sodium azide). 20 µL of these 1/10 dilutions were then placed in U-bottom 96 well plates, before adding 180 µl per well of the Jurkat-S&R mix.

The plates were then incubated for 30 minutes at room temperature before placing them on ice for a further 30 minutes. All subsequent steps were carried out in the cold, with plates and washing buffers kept on ice. After the primary staining, samples were washed in PFN, with resuspending the cells by tapping the plate after each centrifugation, before adding 150 µl of PFN for the next wash. After 2 washes, the samples were split into 4 wells, and all resulting samples were washed one last time.

One drop (i.e. ca. 30 µl) of either the pan-specific anti-Ig-GAM secondary fluorescent
antibodies, as well as anti-IgG, -IgA or -IgM, all diluted 1/200 in PFN was added to each of
the four wells for each sample, and the cells resuspended by gentle shaking of the plates.
After an incubation of 60 min on ice, samples were washed two more times with cold PFN
before transferring the samples to acquisition tubes in a final volume of 300 µl PFN
containing 30 nM TO-PRO™-3 Iodide (Thermo Fischer Scientific, ref T3605).
777
The samples were then analyzed on a FACScalibur flow cytometer controlled by the
Cellquest pro software (Version 5.2, Beckton Dickinson), using the FL1 channel for Alexa-488,
the FL3 channel for m-Cherry, and the FL4 channel (with the 633 nm laser) for live gating
with the TO-PRO™-3 live stain. Post-acquisition analysis of all the samples was performed
using the Flowjo software (version 10.7.1). The values used as results are those for specific
staining, i.e. the difference between the GMFI (geometric mean fluorescent index)
measured on the Jurkat cells expressing the SARS-CoV-2 spike protein and the control Jurkat
cells expressing the mCherry fluorescent protein. The value of 40 of specific staining was
used as the threshold above which the samples were considered as positive. As described
previously, with the cytometer settings used in this study, this correspond to 20 fold the
value obtained with cells stained just with the secondary antibody (Maurel Ribes et al. 2021).
789
FACS analysis of RBCs after HAT
To quantify the amount of antibodies bound to the RBCs' surface after a HAT assay, an
adjustable pipet was used to resuspend the RBCS by pipetting up and down several times,
and 15 µl (out of 90 or 100) were transferred to the well of a U-bottom 96 well plate pre-
filled with 150 µl PFN. The RBCs were then washed by three repeated sequences of
centrifugation at 800 g for 3 min, followed by flicking the supernatant out, tapping the plate,
and adding 150 µl of PFN. One drop (i.e. ca. 30 µl) of anti-human secondary antibody
conjugated to alexa-488, diluted 1/200 in PFN was added to each of the wells, and the cells
resuspended by gentle shaking of the plates. After an incubation of 60 min on ice, samples
were washed two more times with cold PFN before transferring the samples to acquisition
tubes in a final volume of 300 µl PFN. The samples were then analyzed on a FACScalibur flow
cytometer controlled by the Cellquest pro software (Version 5.2, Beckton Dickinson). Post-
acquisition analysis of all the samples was performed using the Flowjo software (version
10.7.1)
804
Because they can be obtained in very large numbers and stored at 4°C for several weeks, it is
actually much simpler to use RBCs for FACS analysis than Jurkat cells, which need to be kept
in culture continuously. But we find that FACS analysis of RBCs has a much reduced dynamic
range compared to the Jurkat-S&R-flow test. It is indeed less sensitive, and many samples
harboring low levels of antibodies would not be detected by RBC staining. And for samples
that contain very high amounts of antibodies, the RBCs will tend to stay agglutinated, and
the resulting cell clumps will be discounted during FACS analyses, with samples containing
much lower numbers of usable cells, and the FACS results skewed towards lower values. If
wanting to perform FACS analysis of RBCs after HAT, a solution to avoid this problem of
clumping is to analyze those samples that are just one or two dilutions above the endpoint.
But this will mean that all samples will not all have been stained with the same amounts of
reagent and consequently that the staining levels cannot be compared with one another.

Alternatively, the problem can also be avoided by keeping the concentrations of the IH4-RBD
below 100 ng/ml, but this will result in a further reduction of the sensitivity for the samples
with low levels of antibodies.
820
821 **Author contributions**
822

Name	First name	ORCID	contributions
Joly	Etienne	0000-0002-7264-2681	Designed and funded the study; Performed the experiments; Wrote the paper.
Maurel Ribes	Agnes	0000-0002-7560-9502	Collected and anonymized blood samples.

823
824 **Other contributors**
825

Townsend	Alain	Designed the IH4-RBD reagents and funded their production. Established the initial HAT protocol
Tiong	Tan	Produced the IH4-RBD reagents
Rijal	Pramilla	Produced the IH4-RBD reagents
Featherstone	Carol	Copy edited parts of the manuscript

827 **Funding**
828 This project was initially funded by a private donation, and subsequently by the ANR grant
829 HAT-field to EJ.
830
Acknowledgements
We are particularly grateful to the following people: Alain Townsend, Tiong Kit Tan, Pramila
Rijal, who contributed the various materials detailed in the above table, and to Carol
Featherstone for copy editing. We also gratefully acknowledge the contributions of
Marianne Navarra, for her help in setting up the agreement with the hospital; Emmanuelle
Naser and Pénélope Viana from the IPBS flow cytometry facility for their assistance; the staff
of the Toulouse EFS (Etablissement Français du Sang) for the provision of O- blood samples;
Florence Abravanel and Jacques Izopet for providing immune sera from convalescent Covid
patients, and Eric Vallée for the experiments he carried out very early on in the course of the
pandemic to compare the performance of HAT with those of the lateral flow assays.

Supplementary material:

1) **Data file for the clinical samples**: With the cohort of 60 clinical samples of whole
blood we used to validate the performance of the modified HAT protocols, we ended
up producing 24 different sets of data. Whilst a good number of different
comparisons between those sets are presented on figures 6 and S1-3, it was not
practical to provide comparisons for all the possibly interesting combinations. With
the sets of data provided as an Excel file, interested reader wanting to explore other
comparisons not provided here can easily perform those.

The data sets provided are as follows:

Column	
A	Sample numbers
HAT-field scores (starting with IH4-RBD at 3.16 µg/ml) Each score increment corresponds to dilution of IH4-RBD by a factor of 3.16	
B	IH4-RBD Wuhan after 60' under normal gravity
C	IH4-RBD Wuhan after 60' + 1' spin @ 100g
D	IH4-RBD Delta after 60' under normal gravity
E	IH4-RBD Delta after 60' + 1' spin @ 100g
F	IH4-RBD Wuhan 1' spin @ 100g after 15' incubation
G	IH4-RBD Delta 1' spin @ 100g after 15' incubation
H	IH4-RBD Wuhan after 1 hour under normal gravity
I	IH4-RBD Wuhan after 3 hours under normal gravity
J	IH4-RBD Wuhan after 5 hours under normal gravity
K	IH4-RBD Delta after 1 hour under normal gravity
L	IH4-RBD Delta after 3 hours under normal gravity
M	IH4-RBD Delta after 5 hours under normal gravity
Titrations on O- RBCs (using 1 µg/ml IH4-RDB) Starting with plasmas @1/50 (score 1) Each score increment corresponds to one further double dilution of plasma	
N	IH4-RBD Wuhan after 60' under normal gravity
O	IH4-RBD Wuhan after 60' + 1' spin @ 100g
P	IH4-RBD Delta after 60' under normal gravity
Q	IH4-RBD Delta after 60' + 1' spin @ 100g
Reactivities on IH4 alone (performed only on those samples which had shown reactivity on IH4 alone @ 1.6 µg/ml) in the initial whole blood screen	
HAT-field scores (starting with IH4 alone at 1.6 µg/ml) Each score increment corresponds to dilution of IH4 alone by a factor of 3.16	
R	IH4 alone after 60' under normal gravity
S	IH4 alone after 60' under normal gravity + 1' spin @ 100g
Titrations on O- RBCs (using 0.5 µg/ml IH4 alone) Starting with plasmas @1/50 (score 1) Each score increment corresponds to one further double dilution of plasma	
T	IH4 alone after 60' under normal gravity
U	IH4 alone after 60' under normal gravity + 1' spin @ 100g
Results of the Jurkat-S&R-flow test (GMFI Jurkat-S – GMFI Jurkat-R)	

V	All human Igs: (red scale was applied to symbolize signal intensities)
W	IgG (blue scale was applied to symbolize signal intensities)
X	IgA (yellow scale was applied to symbolize signal intensities)
Y	IgM (green scale was applied to symbolize signal intensities)
Comparison of the signals obtained for IgG / IgA / IgM (bar for negative samples)	
Z	Sums of columns W (IgG) + X (IgA) + Y (IgM)
AA	Percentage of signal for IgG (blue scale)
AB	Percentage of signal for IgA (yellow scale)
AC	Percentage of signal for IgM (green scale)
Clinical information	
AD	Gender of patient
AE	Covid / PCR History

853
854
855

2) **Supplementary figures**:

Figure S1: Influence of the incubation times on HAT-field scores

Figure S2: Spinning of plates for plasma titrations after 60 minutes incubation under normal
gravity also greatly increases sensitivity

Figure S3: Comparing scores obtained with IH4-RBD-delta to those obtained with IH4-RBD
Wuhan

3) Step by step protocol for HAT-field

868
869   **Bibliography**
870
Ertesvåg, N.U., Xiao, J., Zhou, F., et al. 2021. A Rapid Antibody Screening
Haemagglutination Test for Predicting Immunity to Sars CoV-2 Variants of Concern.
Research square.
Habib, I., Smolarek, D., Hattab, C., et al. 2013. V(H)H (nanobody) directed against human
glycophorin A: a tool for autologous red cell agglutination assays. *Analytical Biochemistry*
438(1), pp. 82–89.
Jayathilaka, D., Jeewandara, C., Gomes, L., et al. 2021. Comparison of kinetics of immune
responses to SARS-CoV-2 proteins in individuals with varying severity of infection and
following a single dose of the AZD1222. *medRxiv*.
Jeewandara, C., Guruge, D., Abyrathna, I.S., et al. 2021. Seroprevalence of SARS-CoV-2
Infection in the Colombo Municipality Region, Sri Lanka. *Frontiers in public health* 9, p.
724398.
Jeewandara, C., Kamaladasa, A., Pushpakumara, P.D., et al. 2021. Immune responses to a
single dose of the AZD1222/Covishield vaccine in health care workers. *Nature
Communications* 12(1), p. 4617.
Kemp, B.E., Rylatt, D.B., Bundesen, P.G., et al. 1988. Autologous red cell agglutination
assay for HIV-1 antibodies: simplified test with whole blood. *Science* 241(4871), pp. 1352–
1354.
Kenny, G.E. and Dunsmoor, C.L. 1983. Principles, problems, and strategies in the use of
antigenic mixtures for the enzyme-linked immunosorbent assay. *Journal of Clinical
Microbiology* 17(4), pp. 655–665.
Kruse, R.L., Huang, Y., Lee, A., et al. 2021. A Hemagglutination-Based Semiquantitative
Test for Point-of-Care Determination of SARS-CoV-2 Antibody Levels. *Journal of Clinical
Microbiology* 59(12), p. e0118621.
Lamikanra, A., Nguyen, D., Simmonds, P., et al. 2021. Comparability of six different
immunoassays measuring SARS-CoV-2 antibodies with neutralising antibody levels in
convalescent plasma: from utility to prediction. *Transfusion*.
Maurel Ribes, A., Bessiere, P., Guery, J.-C., et al. 2021. A simple, sensitive and quantitative
FACS-based test for SARS-CoV-2 serology in humans and animals. *medRxiv*.
ter Meulen, J., van den Brink, E.N., Poon, L.L.M., et al. 2006. Human monoclonal antibody
combination against SARS coronavirus: synergy and coverage of escape mutants. *PLoS
Medicine* 3(7), p. e237.
Redecke, V., Tawaratsumida, K., Larragoite, E.T., et al. 2021. A rapid and affordable point of
care test for antibodies against SARS-CoV-2 based on hemagglutination and artificial
intelligence interpretation. *Scientific Reports* 11(1), p. 24507.
Townsend, A., Rijal, P., Xiao, J., et al. 2021. A haemagglutination test for rapid detection of
antibodies to SARS-CoV-2. *Nature Communications* 12(1), p. 1951.
Wegmann, T.G. and Smithies, O. 1966. A simple hemagglutination system requiring small
amounts of red cells and antibodies. *Transfusion* 6(1), pp. 67–73.
Wegmann, T.G. and Smithies, O. 1968. Improvement of the microtiter hemagglutination
method. *Transfusion* 8(1), p. 47.
Wilson, K.M., Gerometta, M., Rylatt, D.B., et al. 1991. Rapid whole blood assay for HIV-1
seropositivity using an Fab-peptide conjugate. *Journal of Immunological Methods* 138(1), pp.
111–119.
Zhou, D., Duyvesteyn, H.M.E., Chen, C.-P., et al. 2020. Structural basis for the neutralization
of SARS-CoV-2 by an antibody from a convalescent patient. *Nature Structural & Molecular
Biology* 27(10), pp. 950–958.
918

| Sample n° | HAT-field | | | | | | | | | | | | Titration on O- RBCs | | | | reactivity on IH4 alone | | | | Jurkat S&R flow results | | | | | | | | Clinical data | |
| | Wuhan | | Delta | | Wuhan | Delta | Wuhan | | | Delta | | | Scores titration Wuhan | | Scores titration Delta | | HAT-field scores | | titrations on 0.5 ug/ml | | | | | | | | | | | |
	60 min 1g	+ spin	60 min 1g	+ spin	Spin @ 15 min	Spin @ 15 min	1 hour	3 hours	5 hours	1 hour	3 hours	5 hours	1 hour	+ spin	1 hour	+ spin	60 min	+ spin	60 min	+ spin	J-S&R 488 GAM	G	A	M	G+A+M	%G	%A	%M	Gender	Covid / PCR histories
1	3	5	2	4	5	4	3	4	5	3	3	4	3	5	3	5					158.79	172.32	4.61	1.26	178.2	96.7	2.6	0.7	F	
2	0	0.5	0	0	0.5	0	0.5	0.5	0.5	0	0	0.5	1	2	0.5	2					38.1	42.29	3.01	0.6	45.9	92.1	6.6	1.3	F	
3	4	4	3	3	4	3	3	4	4	3	3	3	7	8	7	8					215.78	190.72	16.58	92.68	300.0	63.6	5.5	30.9	M	
4	0	0	0	0	0	0	0	0	0	0	0	0	0	0.5	0	0.5					2.7	2.58	1.12	2.47	6.2				M	
5	1	2	0	0	2	0	0.5	1	1	0	0	0	3	5	1	2					61.5	64.1	2.51	2.18	68.8	93.2	3.6	3.2	M	Covid in oct 2020 (PCR pos)
6	4	6	4	5	6	5	4	5	6	4	5	6	5	8	6	8			2	4	907.4	1066.14	27.12	9.1	1102.4	96.7	2.5	0.8	F	
7	0.5	4	0	3	4	4	0.50	2	4	0	2	4	3	5	2	4					355.65	380.74	8.34	5.53	394.6	96.5	2.1	1.4	F	
8	0	1	0	0.5	1	1	0	0.5	0.5	0	0.5	1	0.5	1	0	0.5					62.3	67.7	2.38	12.4	82.5	82.1	2.9	15.0	F	pos PCR on hosp entry, neg on day 4
9	5	6	3	6	6	6	5	6	6	4	6	7	6	8	5	7					981.27	1173.48	53.72	13.02	1240.2	94.6	4.3	1.0	M	
10	3	6	3	5	7	6	3	5	5	3	4	5	2	4	2	4					569.08	693.8	52.4	1.48	747.7	92.8	7.0	0.2	M	
11	0	0	0	0.5	0	0.5	0	0	0	0	0	1	0	0	0	0.5					6	6.55	0.95	0.51	8.0				F	pos PCR, with L452R mutation
12	6	7	6	7	7	7	6	7	7	6	7	7	5	7	6	8	0	1	0.5	1	1401.39	1643.68	208.3	8.94	1860.9	88.3	11.2	0.5	F	
13	1	3	0	1	2	2	1	2	3	0	1	2	2	4	2	3					195.9	242	20.03	2.8	264.8	91.4	7.6	1.1	F	
14	4	5	3	4	5	4	3	4	5	3	4	5	5	7	5	7					862	962.53	117.14	7.33	1087.0	88.5	10.8	0.7	M	
15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					2	1.38	0.56	-0.12	1.8				M	
16	0	2	0	1	2	1	0	0.5	2	0	0	1	2	4	2	3					614.49	716.92	63.03	6.12	786.1	91.2	8.0	0.8	F	
17	0	0	0	0	0	0	0	0	0	0	0	0	0.5	1	0.5	1			0	1	4.81	6.68	0.81	-0.17	7.3				M	
18	5	6	4	5	6	5	5	6	7	4	5	6	5	7	5	7					1338.19	1519.39	96.39	2.43	1618.2	93.9	6.0	0.2	M	
19	3	3	2	2	3	2	2	3	3	2	2	3	5	7	5	6	3	3	5	6	7.1	17.7	0.83	-13.34	5.2				M	
20	0	0.5	0	0.5	1	0.5	0	0	0	0	0	0	1	3	1	2					125.99	114.68	84.24	0.46	199.4	57.5	42.3	0.2	F	
21	5	6	4	6	7	6	5	6	6	4	5	7	5	7	5	7					1518.52	1977.44	48.5	2.46	2028.4	97.5	2.4	0.1	M	
22	1	3	0	0.5	3	1	1	2	3	0	0	1	3	5	2	2					40.76	40.25	34.41	0.02	74.7	53.9	46.1	0.0	F	
23	3	5	3	4	5	4	3	4	5	3	4	5	4	6	4	5					705.9	879.85	8.41	1.87	890.1	98.8	0.9	0.2	F	
24	0	0.5	0	0.5	0.5	0.5	0	0	1	0	0	0.5	2	4	1	3			0.5	1	318.73	320.2	121.44	-0.11	441.5	72.5	27.5	0.0	M	
25	1	2	0	0	2	0	1	1	2	0	0	0	3	4	1	2					87.95	107.31	6.93	-0.47	113.8	94.3	6.1	-0.4	M	
26	1	4	1	3	4	3	1	3	4	1	2	3	2	4	2	3					285.97	324.66	8.35	1.21	334.2	97.1	2.5	0.4	F	
27	7	7	7	7	7	7	7	7	7	7	7	7	5	8	6	8					2380.5	2648.33	77.85	57.1	2783.3	95.2	2.8	2.1	F	
28	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0.5	1					46.96	48.95	9	5.63	63.6	77.0	14.2	8.9	M	
29	0	0	0	0	0	0	0	0	0	0	0	0	0.5	1	0	0.5					15.77	17.49	8.09	0.33	25.9	67.5	31.2	1.3	M	
30	0	0.5	0	0.5	0	0	0	0	0	0	0	0	2	3	2	3					201.07	244.52	4.3	0.4	249.2	98.1	1.7	0.2	M	
31	5	6	5	6	6	6	5	6	7	5	6	6	5	7	6	8					639.8	808.96	20.27	7.3	836.5	96.7	2.4	0.9	F	
32	0	1	0	0	1	0	0	0	0	0	0	0	0.5	1	0	0.5					55.4	64.96	6.78	-0.89	70.9	91.7	9.6	-1.3	F	
33	2	5	2	4	5	5	2	4	5	2	3	5	3	5	3	5					651.5	741.8	24.21	-0.85	765.2	96.9	3.2	-0.1	F	
34	6	7	6	6	7	7	5	7	7	6	7	7	7	8	7	8					1850.82	2295.06	97.08	59.12	2451.3	93.6	4.0	2.4	F	
35	0	0	0	0	0	0	0	0	0	0	0	0	0	0.5	0	0					3.11	4.31	2.3	-1.44	5.2				M	
36	4	6	4	6	6	6	4	6	6	4	5	6	4	6	4	6					892.12	1022.68	10.7	2.02	1035.4	98.8	1.0	0.2	M	
37	5	6	4	6	6	6	5	6	6	4	5	6	4	7	5	6					1191.18	1434.3	30.3	7.2	1471.9	97.4	2.1	0.5	M	
38	0	0	0	0	0.5	0	0	0.5	0.5	0	0	0.5	0.5	1	0	1					66.32	82.9	2.4	2.7	88.1	94.2	2.7	3.1	M	
39	2	4	2	3	5	3	2	3	4	2	3	6	2	3	1	2	0	1	1	2	265.7	324.3	27.8	0.6	352.7	91.9	7.9	0.2	M	
40	0.5	2	1	2	4	2	0.5	2	2	1	1	2	2	4	2	3					296.58	365.3	15.4	0.3	381.0	95.9	4.0	0.1	F	
41	0	0	0	0.5	0.5	0.5	0	0	0	0	0	0.5	0.5	1	0.5	1					106.9	122.0	32.7	-0.3	154.5	79.0	21.2	-0.2	F	
42	0	1	0	1	2	1	0	1	2	0	0	1	2	4	1	3					236.46	287.6	11.8	1.1	300.4	95.7	3.9	0.4	M	
43	5	5	4	5	7	6	5	6	6	4	5	6	4	5	4	5					485.3	573.2	19.5	4.8	597.5	95.9	3.3	0.8	F	
44	5	6	4	5	6	5	5	5	6	4	5	5	6	8	6	7					1072.98	1443.3	82.8	46.9	1573.0	91.8	5.3	3.0	M	
45	1	2	0.5	2	3	3	1	2	3	0.5	2	3	3	5	2	4					542.57	735.6	8.7	1.7	746.0	98.6	1.2	0.2	M	
46	2	4	2	3	5	4	2	4	4	2	3	4	4	5	4	5			0.5	1	481.13	595.9	5.4	2.2	603.5	98.7	0.9	0.4	M	
47	0	0	0	0	2	2	0	0	0	0	0	0	1	2	1	2					116.7	145.7	1.5	1.0	148.2	98.3	1.0	0.7	M	
48	0	0.5	0	0.5	0.5	0.5	0	0.5	0.5	0	0	0.5	0.5	0.5	0.5	0.5			2	3	44.85	53.7	3.2	7.7	64.6	83.2	4.9	11.9	M	
49	0	0.5	0	0.5	0.5	0	0	0	0	0	0	0	1	2	0	0.5					17.1	20.4	2.1	0.5	23.0	88.9	8.9	2.1	M	
50	0	0.5	0	1	0.5	1	0	0	0	0	0	0.5	2	3	2	3			0.5	1	93.89	107.3	1.8	2.4	111.5	96.3	1.6	2.2	F	
51	0	0.5	0	0.5	0.5	1	0	0	0	0	1	0.5	1	2	0.5	1					20.74	23.1	1.8	2.3	27.1	85.2	6.5	8.3	F	
52	4	4	2	3	4	3	3	4	4	2	3	3	3	4	3	3	0	1	2	2	275.1	294.9	10.7	11.8	317.4	92.9	3.4	3.7	M	
53	2	4	1	3	4	3	2	3	4	1	3	4	3	6	4	5					224.83	223.7	100.5	0.5	324.6	68.9	30.9	0.1	M	
54	4	6	2	5	5	4	4	5	5	3	4	4	4	7	5	7					567.1	716.5	6.6	-0.3	722.8	99.1	0.9	0.0	M	
55	0.5	2	1	2	3	2	0.5	1	2	1	1	2	2	4	2	3			0	1	287.5	310.8	312.8	0.3	623.9	49.8	50.1	0.0	M	
56	0	1	0	0.5	1	1	0	0.5	0.5	0	1	1	1	2	1	1					82.8	101.4	21.6	-1.1	121.9	83.2	17.7	-0.9	M	
57	7	7	6	7	7	7	7	7	7	6	7	7	7	8	8	8					1279.28	1765.8	21.8	55.5	1843.2	95.8	1.2	3.0	M	
58	0	0	0.5	1	1	1	0	0	0	0	0	0	0	0	0	0.5					2.6	5.3	1.9	0.1	7.3				M	
59	0.5	3	0.5	2	3	3	0.5	2	3	0.5	2	2	2	3	2	3	1	1	0.5	2	165.94	199.9	6.8	0.3	207.0	96.6	3.3	0.2	F	
60	4	6	4	6	6	6	4	6	6	4	5	5	5	7	5	7					864.11	1190.2	13.2	8.2	1211.6	98.2	1.1	0.7	F	

Supplementary figures

Supplementary figure 1: Influence of the incubation times on HAT-field scores

For each of the 60 samples of the cohort of clinical whole blood samples, HAT-field was setup in three separate parallel plates, as described in Methods. The three separate plates were then submitted to the following incubation conditions:

i) Under normal gravity (1g), with tilting and taking pictures at 1, 3 and 5 hours before returning the plates to a horizontal position each time.

ii) under normal gravity for one hour, then taking pictures before and after spinning the plates for 1 minute at 100g

iii) incubating the plates for just 15 minutes horizontally at 1g before spinning it for 1 minute at 100g and then taking the pictures.

This resulted in 6 data sets, which were all compared to the values of the Jurkat-S&R-flow test (first two lines). The vertical doted red lines indicate the threshold for positive samples used for the Jurkat-S&R-flow test.

For the HAT-field test, although we recorded the partially hemagglutinated wells at the highest IH4-RBD concentration as a value of 0.5, we only consider the fully hemagglutinated wells as truly positive (score 1).

Comparison of the 3 graphs on the first line shows that, when the plates are incubated under normal gravity, the sensitivity of the detection increases with incubation times, with fewer and fewer samples identified as positives by the Jurkat-S&R-flow test (i.e. past the red line) with HAT-field scores of zero or 0.5.

The first graph on the second line is effectively a repeat of the one just above, i.e. 1g for 60 minutes. Comparison of the two shows that, although there are minor differences (i.e. the

HAT-field scores of a few samples differing by just one unit), the method is highly reproducible.

The next two graphs correspond to the results obtained after spinning the plates at 100g for 1 minute after either 60 minutes (2nd graph) , or after just 15 minutes (3rd graph), giving results that are very comparable to one another, and to those obtained after incubating the plates for 5 hours under normal gravity.

The graphs on the third line are one on one comparisons between the sets of scores obtained under these three latter conditions, i.e. 1g for 1 hours then spin, 1g for 5 hours, or 1g for just 15 minutes before spinning. Although the results obtained with those three conditions are very closely related to one another, it is worthy of note that spinning the plates after just 15 minutes does result in a few samples with slightly higher scores than those obtained with the other two conditions.

Supplementary figure 2: Spinning of plates for plasma titrations after 60 minutes incubation under normal gravity also greatly increases sensitivity.

A can be seen by comparing the two graphs below, when performing plasma titrations using the standard HAT protocol, spinning the plate after 60 minutes of incubation at 1g (right panel) results in a marked improvement of the sensitivity, with all of the samples that were detected as positive by FACS having a HAT score of at least 1, i.e. showing full hemagglutination at 1/40, the highest plasma concentration used. The one sample which gave partial hemagglutination and FACS signal just above the positive threshold was actually most probably a false positive (see figure 6 and sample 48 in data file).
See Discussion for considerations relating to the importance of using the IH4 alone reagent as a negative control to counter the decrease in specificity linked to increased sensitivity.

Supplementary figure 3: Comparing scores obtained with IH4-RBD-delta to those obtained with IH4-RBD Wuhan

The above graphs were generated using:
For HAT-field, the scores obtained after spinning the plates at 100g for 1' after 15' incubation at 1g (columns F for Wuhan and G for Delta in the data file).
For the plasma titrations, the scores obtained after spinning the plates at 100g for 1' after 60' incubation at 1g (columns O for Wuhan and Q for Delta in the data file).

The first graph shows that, as was seen in figure 6 with the IH4-RBD Wuhan reagent, under the conditions used in this study, plasma titrations are more sensitive than HAT-field.

The second and third graph show that, for both HAT-field and plasma titrations, the scores obtained with the IH4-RBD Delta reagent tend to be similar or lower by one or two units than those with the IH4-RBD Wuhan reagent.

The validation of the optimized HAT protocols was performed on a cohort of clinical whole blood samples collected in the course of the month of September 2021. At that time, most of the SARS-CoV-2 virus circulating in France belonged to the Delta lineage. Since those were blood samples from hospitalized patients, we were expecting to find a sizeable proportion of Delta-infected patients. Somewhat disappointingly, gathering of clinical information on the patients from which the blood samples were obtained, which took place after the experiments were carried out, actually revealed that, in our cohort of 60 samples, only 3 were from patients who had ever had a positive PCR for SARS-CoV-2.

The first patient (sample 5, red spots) had had a positive PCR in October 2020, and must thus have been infected by a viral strain different from delta. The level of the plasmatic anti-spike antibodies measured by the Jurkat-S&R-flow test was low (specific staining signal of 61.5), dominantly of the IgG isotype (93.2 %), and higher HAT scores with the Wuhan IH4-RBD than with the Delta IH4-RBD: HAT-field : W=2, D=0 ; HAT titration: W= 5, D=2

The second patient (sample 8, yellow spots) had a positive PCR on admission, which was the day when the blood sample we used was collected, but no information on viral genotyping was available. A PCR carried out 4 days later was negative. The level of the plasmatic anti-spike antibodies measured by the Jurkat-S&R-flow test was also low (specific staining signal of 62.3), with a sizeable signal for IgMs (15%). HAT scores were only just positive: HAT-field :

W=1, D=1; HAT titration: W= 1, D=0.5. Based on this limited amount of information, no conclusion can be drawn regarding the lineage of the virus that infected that patient.

The third patient (sample 11, green spots) had a positive PCR on admission, which revealed a viral strain carrying the L452R corresponding to the delta lineage. No further information is available about the evolution of the infection. Plasmatic anti-spike antibodies were undetectable with the Jurkat-S&R-flow test (specific staining signal of 6). Among the 16 sets of HAT scores (columns B-Q), although none were clearly positive, three were recorded as partially positive, all with the IH4-RBD Delta reagent : HAT-field 60' + spin and 15' + spin, and titration 60' + spin.

Although the data obtained for those three samples can only be considered as anecdotal, it is nonetheless comforting to see that they all follow the expected direction. A properly setup clinical trial, enrolling larger numbers of patients infected by various strains of the SARS-CoV-2 virus would need to be setup to formally validate the performance of the two reagents, and their capacity to follow serological responses after infection with those various strains. This was, however, far beyond the reach of this study.

Protocol for HAT-field

(Etienne Joly, atnjoly@mac.com)

Hatfield Palace

Equipment Required

Equipment for laboratory procedures
- Adjustable pipets + tips
- 15 ml tubes and 10 ml pipets
- Small tubes (e.g. Eppendorf tubes)
- V bottom 96 well plate (e.g. Sarstedt 82.1583)

Reagents
- **RBC dilution** = PBS + 2 mM EDTA
- **PBN** = PBS + 1% BSA + 200 mg/l azide
- **100 X Stock of IH4 alone** @ 240 µg/ml in PBN
- **100 X Stock of IH4-RBD** @ 475 µg/ml in PBN
- Control Antibody CR3022 @ 20 ng/ml in PBN (other mAbs, e.g. EY6A can also be used)

Equipment for HAT-field procedure
- Disposable lancets (e.g. Sarstedt 85.1016) , sterile swabs, alcohol
- Small tubes (e.g. Eppendorf tubes) containing 300 µl of RBC dilution (PBS + 2 mM EDTA)
- Plastic Pasteur pipettes (small volume e.g. Sarstedt 86.1180)
- V bottom 96 well plates, if possible prefilled with 60 µl/well of working solutions (see below).

Preparation of working solutions:

Rather than simple DD, we elected to use a factor of 3.16 between successive dilutions. This not only allows to cover a larger range of IH4-RBD concentrations, but because 3.16 is the square root of 10, two successive dilutions correspond to a factor of 10. The concentrations of the IH4-RBD stocks used to prefill the wells will thus be, in ng/ml 4750, 1500, 475, 150, 47, 15, 4.7. After addition of one drop of diluted blood, i.e. roughly 30 µl, the approximate final concentrations of IH4-RBD in the wells will thus be, in ng/ml: 3160, 1000, 316, 100, 31, 10, 3.

Label eight 15 ml tubes: IH4 Control, and 1 to 7

Tube IH4 Control, will contain 10 ml PBN + 100 µl **100 X Stock of IH4 alone** @ 240 µg/ml in PBN

To perform serial dilutions of the IH4-RBD working solutions

1) Place 14.85 ml PBN in tube n°1, and 10.25 in all others.

2) Add 150 µl of 100 X IH4-RBD Stock to Tube n°1 > 4.75 µg/ml IH4-RBD

3) Use 10 ml pipet to transfer 4.75 ml to tube n°2 > 1.5 µg/ml IH4-RBD

4) Use the same 10 ml pipet to transfer 4.75 ml to tube n°3 > 470 ng/ml IH4-RBD

5) Use the same 10 ml pipet to transfer 4.75 ml to tube n°4 > 150 ng/ml IH4-RBD

6) Use the same 10 ml pipet to transfer 4.75 ml to tube n°5 > 47 ng/ml IH4-RBD

7) Use the same 10 ml pipet to transfer 4.75 ml to tube n°6 > 15 ng/ml IH4-RBD.

7) Use the same 10 ml pipet to transfer 4.75 ml to tube n°7 > 4.7 ng/ml IH4-RBD.

NB: Tube n°7 will contain 15 mls whilst the others will contain just 10.25 ml.

Once prepared, the working solutions can be kept for several weeks, or even months, at either 4°C or room temperature without any noticeable loss of activity.

HAT-field Procedure

Plate preparation:

If an adjustable pipet is available, use it to prefill the wells of a V-bottom 96-well plate with 60 µl/well of the various working solutions (Column 1: IH4 negative control, Columns 2-8 : IH4-RBD dilutions 1 to 7)

If out in the field with no access to an adjustable pipet, the reagent can be distributed just before the assay will be performed, using a plastic Pasteur pipet to dispense 2 drops (i.e. ca. 60 µl) of the working solutions in the appropriate wells, and working in increasing order of concentrations (IH4-RBD dilutions 1 to 7), and a different pipet for the IH4 nanobody negative control.

Blood collection and assay (Subject should be asked to clean hands with soap, using warm water if possible, and to dry them well so that the blood drop stays compact on the fingertip).

- Take a plastic Pasteur pipet, and make sure that you have spotted the limit between the first and second section, which corresponds to 10 µl. Take one of the small tubes with 300 µl of PBS-EDTA, and label it with the subject's name.

- Wipe finger pulp with sterile towel/swab. Prick skin on the outside of finger pulp with disposable, single use lancet. Wipe away first drop with same sterile swab

- Massage second drop of blood to the size of a lentil

- Take up 10 µl with the Pasteur pipet (first section filled) , and transfer this blood to the small tube containing 300 µl of PBS-EDTA. Pipet up and down a couple of times, avoiding making bubbles.

- Using the same Pasteur pipet, take up all 310 µl of diluted blood, and distribute one drop into each of the 8 adjacent wells of a row, containing the IH4 control and IH4-RBD dilutions 1 to 7.

- Incubate the plate in a horizontal position for a minimum of 1hr at ambiant temperature. The red blood cells will sediment and form red dots at the bottom of the wells. Alternatively, if a plate centrifuge is available, plates can be spun at 100g for 1 minute after just 15 minutes incubation.

- Tilt plate at ca. 10° from the vertical against a well-lit white background (if possible on a lightbox, see below)

- When the RBCs have formed teardrops that reach all the way to the walls of the control wells (this should normally take less than 30 seconds), take photographs of the plate to record the results (with a smartphone, for example), making sure the camera is at least 50 cms away from the plate so that the bottom of all the wells can be clearly seen in the pictures. For this, we find that a very simple lightbox can greatly improve the ease of tilting the plates, and the quality of the pictures (see tutorial on https://youtu.be/e5zBYd19nIA)

- Scoring of the samples is done by counting the wells from the highest IH4-RBD concentration to the last well showing complete hemagglutination, i.e. a symmetrical dot with no "pointy bottom" as a result of the tilting.

<u>Remarks:</u>

When performing the assay for the first time, once the 10 µl of blood have been diluted in the 300 µl PBS-EDTA, it is a good idea to start by counting the drops you will obtain by dropping them back into the tube used for the dilution, so as to ensure that you can obtain 8 drops (each drop should be just under 30 µl). If you do not, try placing the pipet at a different angle to generate smaller drops.

If a plate centrifuge is not available, longer incubations, up to 5 hours, will results in increased sensitivity. To this end, plates can be photographed after one hour, then returned to the horizontal position, and the tilting/photographing repeated at 3 and 5 hours (or other times if more convenient).

Rather than PBN, the negative control should preferably consist of the IH4 nanobody at a final concentration of 1.5 µg/ml (i.e. corresponding to the molar concentration of the IH4-RBD reagent in tube 1). Samples that show reactivity against IH4 will then have to be excluded.

Alternatively, a second row of wells containing titrations of the IH4 nanobody alone can be used to assess the plasmatic reactivity against the IH4 moiety of the IH4-RBD reagent. For this, collect 20 µl of blood by filling the plastic Pasteur pipet to the second section, and dilute this blood in 600 µl of PBS-EDTA, before using the pipet to place one drop in the 16 wells of the two rows.

For better quality photographs, it is best to use a lightbox. A very simple and cheap lightbox can be made with a cardboard box and a small lamp, such as the examples below, and in the tutorial video found at the end of this link: https://youtu.be/e5zBYd19nIA

If there are no positive samples in the set tested, the activity of the IH4-RBD can be ascertained by using a plastic Pasteur pipet to add one drop of the CR3022 mAb at 20 ng/ml to all the wells of one row. After returning the rest of the CR3022 stock to its tube, that same pipet can then be used to resuspend the RBCs in all the wells of that row, starting by the well with the lowest concentration of IH4-RBD and working towards higher concentrations, avoiding the formation of bubbles as much as possible. After a further hour of incubation, if stocks of IH4-RBD and CR3022 are fully functional, the endpoint should be around a score of 5.

Examples of lightboxes made with battery-operated LED spotlights

Materials:
1 small carboard box
1 sheet of white printer paper folded in two
1 small lamp with cold bulb (e.g. LED)
Sticky tape and Stanley knife or sharp scissors
Optional: Alu foil to enhance brightness and to obtain more diffuse light.

Method:
1) Use a 96-well plate to cut a window to the right size in the bottom of the box
2) The pieces of cardboard that have been cut out can be used to make 'wings' that will be taped to the bottom so that the box rests at roughly 10° (see pictures)
3) Tape the folded piece of white paper to the inside of the window cut in the bottom
4) The outer flaps at the top of the box can the wrapped in tin foil to provide a brighter a more diffuse light
5) If a 'clamp' lamp is being used, it can be good to increase the thickness of the cardboard by foling the flap over on the side where the lamp will be clamped.
6) For better pictures, turn the lights off in the room, and place the camera at least 50 cms from the plate.

Home-made trans-illuminator for taking picture of HAT plates